- Home
- BILI vs TXMD Comparison
BILI vs TXMD Comparison
Compare BILI & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BILI
- TXMD
- Stock Information
- Founded
- BILI 2009
- TXMD 2008
- Country
- BILI China
- TXMD United States
- Employees
- BILI N/A
- TXMD N/A
- Industry
- BILI EDP Services
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- BILI Technology
- TXMD Health Care
- Exchange
- BILI Nasdaq
- TXMD Nasdaq
- Market Cap
- BILI N/A
- TXMD 12.8M
- IPO Year
- BILI 2018
- TXMD N/A
- Fundamental
- Price
- BILI $20.84
- TXMD $1.14
- Analyst Decision
- BILI Strong Buy
- TXMD
- Analyst Count
- BILI 6
- TXMD 0
- Target Price
- BILI $21.58
- TXMD N/A
- AVG Volume (30 Days)
- BILI 3.3M
- TXMD 60.7K
- Earning Date
- BILI 08-21-2025
- TXMD 08-11-2025
- Dividend Yield
- BILI N/A
- TXMD N/A
- EPS Growth
- BILI N/A
- TXMD N/A
- EPS
- BILI N/A
- TXMD N/A
- Revenue
- BILI $3,882,060,637.00
- TXMD $1,841,000.00
- Revenue This Year
- BILI $15.68
- TXMD $427.09
- Revenue Next Year
- BILI $8.68
- TXMD N/A
- P/E Ratio
- BILI N/A
- TXMD N/A
- Revenue Growth
- BILI 21.83
- TXMD 53.55
- 52 Week Low
- BILI $12.72
- TXMD $0.70
- 52 Week High
- BILI $31.77
- TXMD $2.44
- Technical
- Relative Strength Index (RSI)
- BILI 57.47
- TXMD 44.80
- Support Level
- BILI $20.86
- TXMD $0.98
- Resistance Level
- BILI $21.48
- TXMD $1.21
- Average True Range (ATR)
- BILI 0.49
- TXMD 0.09
- MACD
- BILI 0.03
- TXMD 0.00
- Stochastic Oscillator
- BILI 65.21
- TXMD 64.00
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.